Free Trial

Cryo-Cell International Q1 2024 Earnings Report

Cryo-Cell International logo
$7.83 -0.07 (-0.89%)
(As of 12/20/2024 04:32 PM ET)

Cryo-Cell International EPS Results

Actual EPS
$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cryo-Cell International Revenue Results

Actual Revenue
$7.85 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cryo-Cell International Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.

Cryo-Cell International Earnings Headlines

CRYO-CELL International, Inc. trading resumes
This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
CRYO-CELL International, Inc. trading halted, volatility trading pause
See More Cryo-Cell International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cryo-Cell International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cryo-Cell International and other key companies, straight to your email.

About Cryo-Cell International

Cryo-Cell International (NYSEAMERICAN:CCEL) engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

View Cryo-Cell International Profile

More Earnings Resources from MarketBeat

Upcoming Earnings